Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever. All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of…
Description During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical…
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas…
Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans…
Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here…
Syntheia Corp. (‘Syntheia’ or the ‘Company’) (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative…
The Board of CleanTech Lithium announces that the Company has received the following TR-1 notification which is set out…
In a recent interview, Forward Water Technologies (TSXV:FWTC) CEO Howie Honeyman said the company plans to accelerate adoption of…
(TheNewswire) VANCOUVER, BC – The N ewswire – November 15, 2024 Element79 Gold Corp. (CSE: ELEM) (OTC: ELMGF) (FSE:…